Global Ovulation Inducing Drugs Market

Global Ovulation Inducing Drugs Market size is expected to reach US$ 7.17 Bn. by year 2032 at a CAGR of 5.8% during the forecast period.

Global Ovulation Inducing Drugs Market Overview:

Anovulation is an infertility condition in which follicles in a woman's ovary do not mature and release eggs for which ovulation treatment is given. Ovulation induction is a treatment for this condition (ovulate). A number of drugs that stimulate the ovary to develop and release eggs are used to induce ovulation.

Global Ovulation Inducing Drugs Market Dynamics:

Rise in prevalence of infertility in women due to various disorders is the primary factor which boosts the market growth.

The increasing rates of infertility around the world are driving the growth of the ovulation-inducing drugs market. Infertility is described as the inability to conceive after 12 months of trying. The National Survey of Family Growth (NSFG) in the United States in 2018 stated that 15.5 % of all women planning to become pregnant were infertile, and 6.7 % of married women aged 15 to 44 were infertile. Increased age, polycystic ovarian syndrome (PCOS), obesity, and multiple miscarriages all contribute to female infertility. Obesity, stress, smoking, diabetes, Poly Cystic Ovarian Syndrome (PCOS), and other lifestyle disorders and unhealthy diets are on the rise, resulting in increased demand for ovulation-inducing drugs. According to a study published by the United States Department of Health and Human Services (HHS), PCOS is a global health issue that affects one in every ten women of childbearing age across the world in 2019. As a result, increasing gynecological disorders, which lead to lower fertility rates, are expected to fuel the global market.

The side effects of infertility drugs, such as headache, nausea, upper respiratory tract infection, abdominal tenderness, sinus inflammation, mood swings, acne, breast tenderness, weight gain, pelvic discomfort, unexplained bleeding or spotting, vomiting, injection site pain, redness, dizziness, and Ovarian Hyper-Stimulation Syndrome, are limiting the market growth of ovulation-inducing drugs.

The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Ovulation Inducing Drugs Market Segment Analysis:

The global Ovulation Inducing Drugs market is segmented on the basis of Drug Class and Distribution Channel.

Based on Drug Class, the therapeutic drugs segment is expected to hold a dominant market share during the forecast period. The segment is divided into clomiphene and gonadotropins. Clomiphene or Clomid tablets are the most widely used medications. Clomiphene or Clomid tablets (alternatives include Tamoxifen and Letrozole tablets) stimulate follicles and therefore egg development by increasing the pituitary gland's production of follicle-stimulating hormone (FSH). Clomiphene citrate is a widely used medication that is inexpensive, effective when taken orally, has fewer side effects, and is relatively safe for the foetus. It may be used to treat PCOS-related ovulatory infertility.

To know about the Research Methodology :- Request Free Sample Report

Global Ovulation Inducing Drugs Market Regional Insights:

North America is expected to dominate the global market during forecast period.

During the forecast period, North America is projected to dominate the global ovulation-inducing drugs market. This dominance is primarily due to increasing rates of menopausal disorders, urinary infections, thyroid problems, endometriosis, and other conditions among women as a result of busy lifestyles and increased stress. Also, a rising number of new Food and Drug Administration (FDA) drug approvals are expected to propel the market growth over the forecast period. PCOS affects more than 5 a million women of reproductive age, states a study released by the Centers for Disease Control and Prevention in 2019.

The report also helps in understanding Global Ovulation Inducing Drugs Market dynamics, structure by analyzing the market segments and project the Global Ovulation Inducing Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Ovulation Inducing Drugs Market make the report investor’s guide.

Global Ovulation Inducing Drugs Market, Key Developments:

Ferring Pharmaceuticals, a biopharmaceutical corporation headquartered in the United States, purchased the commercialization rights of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd in 2019 for an undisclosed amount. Ferring Pharmaceuticals hopes to expand its portfolio of reproduction-related medicines as a result of the acquisition. The FDA approved Ganirelix Acetate Injection in 2018 for regulating premature luteinizing hormone (LH) levels in women undergoing fertility treatment.

Global Ovulation Inducing Drugs Market Scope: Inquire before buying

Global Ovulation Inducing Drugs Market, By Region:

• North America
• Europe
• South America
• MEA
• APAC

Global Ovulation Inducing Drugs Market, Key players:

• Pfizer Inc.
• Johnson & Johnson Pvt Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Bayer AG
• Sanofi SA
• Abbott Laboratories
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceutical Inc.
• Mylan N.V.
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Reddy’s Laboratories Ltd.
• Intas Pharmaceuticals Limited
• Endo International Inc.
• Ferring Pharmaceuticals Inc.
• Lupin Limited
• Livzon Pharmaceutical Group Inc.
• Torrent Pharmaceuticals Ltd.
• Gedeon Richter Plc
• Glenmark Pharmaceuticals Ltd.
• Fresenius Kabi AG
• Zydus Pharmaceuticals USA Inc.
• Serum Institute of India Ltd.
• EMD Serono Inc.
• Cipla Inc.